Briefing Paper

Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB

OPTN/UNOS Operations and Safety Committee

Prepared by: Susan M. Tlusty
UNOS Policy Department

Contents

Executive Summary 1
What problem will this resource address? 2
Why should you support this resource? 2
How was this resource developed? 2
How well does this resource address the problem statement? 3
Was this resource changed in response to public comment? 4
Which populations are impacted by this resource? 6
How does this resource impact the OPTN Strategic Plan? 6
How will the OPTN implement this resource? 6
How will members implement this resource? 6
Transplant Hospitals 6
OPOs 6
Histocompatibility Laboratories 6
Will this resource require members to submit additional data? 6
How will members be evaluated for compliance with this resource? 7
How will the sponsoring Committee evaluate whether this resource was successful post implementation? 7
Guidance Document 8
Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB

Affected Policies: N/A
Sponsoring Committee: Operations and Safety
Public Comment Period: January 22, 2018 –March 23, 2018
Board of Director’s Date: June 11-12, 2018

Executive Summary

The OPTN/UNOS Operations and Safety Committee (the Committee) has updated the Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB, originally developed by the Committee and approved by the OPTN/UNOS Board of Directors in June 2011.

Since the original publication, the Committee sponsored major revisions to ABO policies that were approved by the OPTN/UNOS Board of Directors and were implemented in June 2016. During that process, the Committee identified the need to revise the subtyping guidance, as many questions emerged related to subtyping. Questions and identified issues include lab result nomenclature, results interpretation, and incomplete knowledge of policy requirements.

In addition, the revised Kidney Allocation System (KAS) went into effect in December 2014. It eliminated variances (including subtyping variances). KAS put use of subtyped deceased donors into policy to help promote greater access to kidneys for blood type B candidates. Allocation of kidneys using subtyped donors has increased. Pre-KAS there were 19 transplants (0.2% of all kidney transplants) using subtyped donors for blood type B candidates. Post-KAS (year 2) that number rose to 168 (1.4% of all kidney transplants).

The revised guidance document is one part of several educational efforts to assist members with subtyping. Nearly a quarter of OPOs had a subtyping issue cited on their last site survey. Professional Education developed a subtyping e-learning module in response to these concerns. The guidance document is cited as a resource. It needs to be updated to complement the efforts aimed at improving compliant subtyping practices and reporting.

Changes made to the guidance document include:

- Updated OPTN Policy references
- Amended information about special considerations such as neonates
- Updated additional complementary resources
- Revised structure and addition of key points
- Modified language to read more as a plain language document
What problem will this resource address?

Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB was developed and approved by the Board of Directors in June 2011. Since the original publication, the Committee sponsored major revisions to ABO policies that were approved by the OPTN/UNOS Board of Directors and were implemented in June 2016. During that process, the Committee identified the need to revise the subtyping guidance, as many questions emerged related to subtyping. Questions and identified issues include lab result nomenclature, results interpretation, and incomplete knowledge of policy requirements.

In addition, the revised Kidney Allocation System (KAS) went into effect in December 2014. It eliminated variances (including subtyping variances). KAS put use of subtyped deceased donors into policy to help promote greater access to kidneys for blood type B candidates. Allocation of kidneys using subtyped donors has increased. Pre-KAS there were 19 transplants (0.2% of all kidney transplants) using subtyped donors for blood type B candidates. Post-KAS (year 2) that number rose to 168 (1.4% of all kidney transplants).

The guidance document is still a valuable and requested resource. Members and UNOS staff identify subtyping issues. These issues include lab result nomenclature, results interpretation, and incomplete knowledge of policy requirements. Nearly a quarter of OPOs had a subtyping issue cited on their last site survey. Instructional Innovations developed a subtyping e-learning module in response to these concerns and the guidance document is cited as a resource in the module. It needs to be updated to support efforts to promote compliant subtyping practices and reporting.

The revisions also address questions that have recently been asked regarding other special circumstances such as subtyping neonates.

Why should you support this resource?

This resource is being revised to address identified transplant community needs. It needs to be updated to remain relevant to the community. It was developed in consultation with relevant subject matter experts, stakeholders, and internal staff. It is a free resource to assist members with subtyping education and practices. The revised guidance is a tool that can assist with answering questions, reducing confusion, and promoting effective practices regarding subtyping requirements. The revised guidance also supports other efforts to increase subtyping and availability of organs to candidates with traditionally less access due to blood types. This resource augments other policy initiatives and resources such as ABO policy modifications, KAS, UNOS Connect e-learning modules, and the most recently approved Guidance for Transplant Program Participation in the Transplantation of Non-A1/Non-A1B (A2/A2B) Donor Kidneys into Blood Group B Candidates.

How was this resource developed?

In 2008, a kidney donated from a living donor, whose ABO subtyping completed prior to the donation was reported as non-A1 (e.g. A2), was transplanted into a blood type O recipient resulting in immediate graft rejection and organ failure. Repeat subtype testing of the donor indicated the actual subtype to be A1. In response to this event, the Membership and Professional Standards Committee (MPSC) requested that the Committee examine current OPTN policies to evaluate whether they are adequate to ensure that subtyping of both deceased and living donors is accurately determined and verified.

In April 2010, after data review and discussion, the Committee requested that a group of experts in the field of ABO typing and subtyping be formed to assist with the task. The ABO Subtyping Work Group was created and included representation from American Association of Blood Banks (AABB), a histocompatibility laboratory supervisor, a blood bank medical director, the OPTN/UNOS Histocompatibility Committee, representatives from OSC, and other transplant center and OPO personnel familiar with processes related to allocation of organs based on ABO subtyping. The OSC requested the Work Group to assist the Committee with understanding the current practice of laboratories performing subtype testing and centers requesting completion of such tests. They were also asked to assist in proposing requirements that would be consistent with current laboratory and transplant community practice for ABO subtype testing.
This group developed the guidance as part of their overall work on subtyping issues to address community education needs. Their work also resulted in a policy proposal approved by the OPTN/UNOS Board of Directors in November 2011. Policy changes were made to require two separate specimens and tests for subtyping as well as requiring two-person verification of results prior to reporting results to the OPTN Contractor.

The revised guidance was developed by a work group including members of the Committee. The revision efforts also included three additional subject matter experts: two members who have served on the Histocompatibility Committee and are currently lab directors, as well as one member who is a blood bank expert. The work group met monthly to review the current guidance, research content, discuss current issues, and review new developments in the field.

Support staff to the Operations and Safety Committee contributed to the review. Member Quality staff provided updated feedback on issues that they might still uncover during site surveys such as the need to emphasize that two out of three subtyping results cannot be reported or used for allocation. All tests must indicate the same result in order for use in allocation; otherwise, the donor must be allocated on primary blood type. Other internal support staff reviewed the document and made suggestions to incorporate more plain language.

The work group solicited pre-public comment feedback from the Minority Affairs, Kidney, and Organ Procurement Organization (OPO) Committees. The Kidney Committee provided suggestions to improve readability and organization. As a result, the key points are listed at the beginning of the document for those that might not read the entire guidance. The guidance was presented to the Minority Affairs Committee. No suggestions were made at their monthly call. OPO leadership received an advance copy but did not have pre-public comment feedback. The Operations and Safety Committee will continue to consult with these stakeholders during the public comment process as needed. A revised document was developed and submitted for full Committee consideration. The Operations and Safety Committee voted at their November 2017 monthly conference call to send the revised guidance document for January 2018 public comment consideration.

How well does this resource address the problem statement?

This resource addresses the issues identified in the problem statement by doing the following:

1. **Updated OPTN Policy references**
   The revised guidance removes language on kidney variance policy that is no longer in effect following the implementation of the new KAS. It also references organ-specific policies (e.g. kidney, kidney-paired donation, and liver). It also cites specific requirements from revised ABO policies that were amended for clarity.

2. **Amended information about special considerations such as neonates**
   Questions have arisen about special yet rare circumstances. For example, members have asked how far back in time does the rule apply requiring a pre-red blood cell transfusion specimen. The Committee has discussed this question but has decided not to specify a timeline in policy or guidance but the guidance offers information on the red blood cell life cycle. It also raises other considerations such as subtyping in neonates. Neonates do not immediately express red blood cell antigens. Members are encouraged to develop relationships and consult with their blood bank. When there is concern that subtyping cannot be accurately conducted, the reasons must be documented and allocation must be based on primary blood type. Other issues known from site surveys are highlighted such as not using two out of three results to determine subtype.

3. **Updated additional complementary resources**
   In 2011, this guidance was the sole OPTN resource. Since then, two UNOS Connect modules that include significant interactive content on subtyping requirements have been developed and released. These are referenced, as well as the recently approved guidance for transplant programs on managing the candidate side of titer monitoring.
4. **Revised structure and addition of key points**

   The guidance has been reformatted to put the most important information first and move the more technical information towards the back. All key points are put in a summary statement up front. This is done to capture those who may have limited time or ability to read the entire document.

5. **Modified language to read more as a plain language document**

   Concerns were expressed that of the information might be more technical than helpful to assist one of the intended audiences of front line OPO staff. Efforts were put in to make the language simpler. Both work group members as well as communication and policy staff reviewed and revised the content to incorporate plain language wherever possible.

The updates, additional guidance, plain language, and reformatting should benefit the transplant community and help increase compliance with subtyping policies as well as promote effective practices. This resource, along with others discussed, should help answer community questions and ultimately help promote application of allocation subtyping policies that aim to increase organ access for certain blood type candidates.

**Was this resource changed in response to public comment?**

Yes, this proposed guidance was amended slightly post public comment. Some changes were made to the document organization and terms used. Other edits were made for clarity and to address further issues that have been observed with interpreting subtyping results.

This proposal went out for public comment during a 60-day period from January 22, 2018 to March 23, 2018. The OPTN/UNOS Kidney Transplantation and MPSC provided comments and supported the guidance document. The proposal passed on the consent agenda in all eleven regions with no additional comments. Other comments were posted by the Association of Organ Procurement Organizations (AOPO); American Society for Histocompatibility and Immunogenetics (ASHI); American Society of Transplantation (AST); American Society of Transplant Surgeons (ASTS) and North American Transplant Coordinators Organization (NATCO). All of these organizations supported the proposal.

The MPSC felt the actual variability between blood banks is not likely to change as a result of this guidance document, so the community may continue to be confused and commit errors when interpreting and reporting donor subtyping results. MPSC members who discussed the guidance did not have any consensus recommendations on some of the issues that cause questions (e.g. red blood cell transfusions). While the Committee felt that having more specifics or timelines might be helpful for OPOs to adopt into their protocols, they ultimately decided that the data do not exist to give more affirmative guidance and that it seemed appropriate to leave those decisions to OPOs, the blood banks, and the labs that they work with.

The Committee requested specific public comment feedback on the following:

*Is guidance sufficient for special considerations (red blood cell transfusions, neonates)? Do you need more detail or policy?*

- **Comment:** ASHI responded that the AABB technical manual states, “adult levels of ABO expression are generally present by age 2 to 4” (page 268, 19th edition). They are concerned that the proposal states that typing for non-A1 based on lectin is sufficient after age 1. That discrepancy could be significant; however, if the blood bank representatives involved in drafting this proposal have no concerns, then ASHI would defer to their experience.

- **Response:** The work group which included two laboratory directors and one blood bank subject matter expert had debated this exact recommendation during guidance development. Ultimately, it was decided not to use this recommendation due to varying interpretations, concerns over eliminating donor subtype ability by routinely using an upper age limit, and differing standards on manufacturer package inserts for anti-A1 lectin. The guidance does not contain a definitive age limit for neonates but advises OPOs to consult with their blood banks and laboratories. Two examples of the package inserts are shown to demonstrate the variability in advice.
• Comment: The AST felt there are times when ABO subtyping is not considered accurate enough and should be avoided. These include after a blood transfusion is given to a particular donor and in neonates. The guidance is sufficient in this regard and provides an appropriate amount of information. It may be helpful, though, to spell out what should NOT be done, based on specific circumstances and label the section of the text as something similar to, “Do not perform ABO subtyping in the following conditions...” Sufficient detail and policy are not present, and we recommend greater clarification about what NOT to do rather than merely suggesting that one should consult a blood banking specialist in those circumstances, because then you open the door for heterogeneous recommendations.

The pediatric transplant community has particular interest regarding ABO guidance in determining subtyping methods for neonates. There is not consensus regarding testing timelines, interpretation of test results, or clinical decision algorithms.

Response: The Committee agreed with the AST suggestion to emphasize what not to do in subtyping. The content was edited and reorganized to highlight these points.

Did we fail to address any other concerns?

• The Kidney Committee unanimously agreed that there were no deficiencies in the guidance document, and that all updates were evidence-supported and well-organized.
• AOPO commented, “We have no related concerns that are not addressed in the updated guidance document.”
• NATCO commented, “The update is clear and no further detail is indicated.”

The Committee also received a question following a presentation of the guidance during a national webinar. A transplant hospital attendee mentioned a situation where subtyping had been performed post-allocation by a transplant hospital. This was after the OPO had reported subtyping to the OPTN and allocated an organ based upon two results did not conflict and were performed in accordance with OPTN subtyping policies. The OPO had obtained a non-A1 result, however the transplant hospital obtained an A1 result. It has been clarified by the OPTN that the third result would be considered a conflicting result and that subtype should not be used for allocation when this occurs. This issue was referred to the Committee for further evaluation.

The following specific changes have been made to the guidance document, post public comment:

• The term “type” replaces the term “group” throughout the document when referring to blood type because that is the term largely used in OPTN Policy and OPO discussions
• All of the "key points" remain at the beginning of the document but are not repeated throughout the various sections
  o The last key point is bolded and reworded to emphasize “what not to do” in response to public comment
  o An additional key point regarding caution not to confuse Rh results with subtype results is added following an OPO member suggestion
• Additional bullets on common issues are included for clarity
• An additional package insert language and citations are included to demonstrate variability
• Language to address “weak” results is edited for clarity
• A sentence is added to address when a transplant hospital conducts its own subtyping and obtains different results. This is considered a conflicting result and allocation must be performed on primary blood type.

The Committee met on April 11, 2018 in Richmond, Virginia, and briefly discussed the issue with an OPO and transplant hospital obtaining conflicting subtype results. The OPO subtyping policy was not written with this situation in mind. This situation will be further discussed by the Operations and Safety Committee’s Patient Safety Advisory Group. They will develop recommendations regarding needs for further guidance, education, operational instructions and policy clarification.
The Committee reviewed all public comments and made minor edits. The Committee voted unanimously (17 in favor-0 opposed) to send the guidance to the OPTN/UNOS Board of Directors for consideration at their June 2018 meeting.

**Which populations are impacted by this resource?**

This guidance document augments existing efforts to promote sound subtyping practices that can widen organ offer access to some blood type B and blood type O candidates.

**How does this resource impact the OPTN Strategic Plan?**

1. *Increase the number of transplants:* There is no impact to this goal.
2. *Improve equity in access to transplants:* There is no impact to this goal.
3. *Improve waitlisted patient, living donor, and transplant recipient outcomes:* There is no impact to this goal.
4. *Promote living donor and transplant recipient safety:* This guidance document originally developed and published in 2011 helps the transplant community understand the fundamentals of subtyping practices and terminology. The revisions will improve the transplant community’s abilities to understand the importance of subtyping and to avoid incorrect results reporting.
5. *Promote the efficient management of the OPTN:* The revised guidance could help decrease questions and therefore decrease member and staff efforts involved in answering questions.

**How will the OPTN implement this resource?**

This proposal will not require programming in UNetSM Professional Education will monitor this proposal for educational needs. The impact to members suggests that an educational offering may not be necessary.

Updated guidance will be posted on the OPTN website.

**How will members implement this resource?**

The overall fiscal impact will be minimal to all member types as this is a guidance document that might be used for staff training.

**Transplant Hospitals**

The fiscal impact to transplant hospitals will be minimal. They might use the updated tool as part of staff training.

**OPOs**

The fiscal impact to OPOs will be minimal. They might use the updated tool as part of staff training.

**Histocompatibility Laboratories**

The fiscal impact to histocompatibility laboratories will be minimal. They might use the updated tool as part of staff training.

**Will this resource require members to submit additional data?**

No, this proposal is a guidance document and does not require additional data collection.
How will members be evaluated for compliance with this resource?

This proposal is a guidance document does not require evaluation for compliance.

How will the sponsoring Committee evaluate whether this resource was successful post implementation?

Although the Committee will not formally monitor this guidance document, support staff will be queried regarding the frequency and type of observed subtyping questions and issues among members. Staff will also review data from the subtyping course available on UNOS Connect as well as monitor website hits accessing the guidance. This will help determine whether the existing resources are being used, whether they are helpful, or whether additional steps need to be taken to assist with subtyping requirements and promotion of increasing access to disadvantaged blood type candidates.
RESOLVED, that the guidance document entitled *Guidance for ABO Subtyping of Organ Donors for Blood Types A and AB*, as set forth below, is hereby approved, effective June 12, 2018.

**Guidance for ABO Subtyping Organ Donors for Blood Types A and AB**

### Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Contents</td>
<td>8</td>
</tr>
<tr>
<td>Summary</td>
<td>9</td>
</tr>
<tr>
<td>Key Points</td>
<td>9</td>
</tr>
<tr>
<td>What is required by OPTN Policy?</td>
<td>10</td>
</tr>
<tr>
<td>Requirements for Blood Type Determination</td>
<td>10</td>
</tr>
<tr>
<td>Requirements for Blood Subtype Determination</td>
<td>10</td>
</tr>
<tr>
<td>What is a Subtype?</td>
<td>10</td>
</tr>
<tr>
<td>Why does it matter?</td>
<td>11</td>
</tr>
<tr>
<td>When should we use and not use subtyping results for allocation?</td>
<td>11</td>
</tr>
<tr>
<td>What can interfere with test results?</td>
<td>11</td>
</tr>
<tr>
<td>Infants and Neonates</td>
<td>11</td>
</tr>
<tr>
<td>What do the results say?</td>
<td>12</td>
</tr>
<tr>
<td>Common issues in subtype reporting:</td>
<td>12</td>
</tr>
<tr>
<td>What should I do when I am not sure how to report results?</td>
<td>12</td>
</tr>
<tr>
<td>More technical information about subtyping</td>
<td>13</td>
</tr>
<tr>
<td>Who can help?</td>
<td>13</td>
</tr>
<tr>
<td>Resources to learn more</td>
<td>13</td>
</tr>
</tbody>
</table>
Summary

The “Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB” was originally developed in 2011. This revised guidance contains updates to OPTN Policy references and additional resources. It provides amended information about special considerations such as neonates. The guidance document is one of several resources to assist OPTN members with subtyping questions and practices. The goal is to continue expanding organ access for candidates through transplanting non-A1 donors.

Key Points

- Persons who are in primary blood groups (also known as blood type) A and AB can be further tested to determine a more specific subgroup (also known as a subtype).
- Subtypes for blood type A include A1, A2, A\text{\textscript{x}}, A\text{\textscript{int}} and others, but the most common is A1.
- If the donor is not subtype A1, it means they have less A antigen on their red blood cells (RBCs) and organs, which allows them to donate to recipients outside of their primary blood type.
- OPTN Policies refer to all subtypes that are not A1 as non-A1. Therefore, a donor who is primary blood type A and subtyping results show that the donor does not have the A1 subtype is referred to as having blood type A, non-A1.
- When reporting to the OPTN Contractor, A2 is used as shorthand for any blood type A subtype other than A1 (i.e. non-A1, negative for A1). A2B is used as shorthand for any blood type AB subtype other than A1B (i.e. non-A1B, negative for A1B).
- Perform subtyping before the donor receives any RBC transfusions.
- Any blood transfusion can affect the accuracy of subtyping results despite the donor’s hemodilution status.
- OPOs and transplant hospitals should consult with their blood banks to consider special issues that might impact results (such as RBC transfusion and neonates) and follow their recommendations.
- It is never acceptable to use two out of three results for a subtype determination. If there are any discrepant results, then only primary type can be used for allocation.
- There are no standards for how laboratories should report ABO subtypes. The International Society for Blood Transfusion Committee on Terminology for Red Cell Surface Antigens has created a standardized numerical format for reporting red cell subtypes, but this is not suitable for everyday communication. Popular terminology often uses terms: A1, A2, A1B, and A2B. OPTN Policies use the term non-A1 for any subtype that is not A1.
- When reviewing results, be cautious not to confuse the Rh factor result with the ABO subtype result.
- Routine testing determines the presence or absence of the A1 antigen only. It does not determine the actual sub-type. Typing is either positive for A1 or negative for A1. This is why the term A, non-A1 is used for a donor that does not have the A1 antigen.
- The absence of A1 does not necessarily equal A2 due to the existence of multiple subtypes.
- **Subtyping results must not be reported to the OPTN Contractor or used for organ allocation when:**
  - The results do not match or indicate the same result. It is never acceptable to use two out of three results.
  - If one result is different, then only primary type must be reported and used for allocation.
• Pre-RBC transfusion specimens are not available for initial and/or confirmatory testing of subtyping.

What is required by OPTN Policy?

The OPTN has several policies that allow the transplantation of donors who have a non-A1 subtype into candidates of other blood types. These policies include:

- Policy 9.7.B: Points Assigned by Blood Type
- Policy 8.5.D: Allocation of Kidneys by Blood Type
- Policy 13.7: OPTN KPD Screening Criteria

Requirements for Blood Type Determination

Clinical policies and information about how to perform transplants that are primary blood type incompatible but are done with certain subtyping results are determined by the transplant program. When these types of transplants are planned, the OPTN has policies about how to determine a subtype for a deceased donor (Policy 2.6.B: Deceased Donor Blood Subtype Determination) or a living donor (Policy 14.5.B: Living Donor Blood Subtype Determination). OPTN policies mandate that all deceased and living donors, as well as candidates, be blood typed on two separate occasions, and these rules apply to subtyping as well. By definition, this means the blood must:

1. Be drawn on two separate occasions
2. Have different collection times
3. Be submitted as separate samples
4. Have results indicating the same blood type

Requirements for Blood Subtype Determination

If testing determines that a deceased donor’s primary blood type is A, then you must also subtype that donor. The only exception to this rule is when no blood samples are available before the donor is given red blood cell (RBC) products. Subtyping is optional for living donors and blood type AB deceased donors. If the donor is found to be blood type A, non-A1, a second subtype must be drawn (different draw time, different draw occasion) for confirmation. It is important to note that:

All subtyping for deceased or living donors must be completed before the donor receives any red blood cell transfusions.

What is a Subtype?

We are all familiar with the blood types A, B, O and AB.

Enzymes that add sugars to form either the type A or the type B antigens determine the blood type. Individuals who are blood type O lack the enzyme to add those sugars and have an H precursor substance that gives them their O blood type. You can find blood type antigens on many cells, including RBCs and cells inside blood vessels of all vascular organs that are routinely transplanted. The reason these blood type antigens are clinically important in transplantation and blood transfusion is that individuals have naturally occurring antibodies to blood type antigens they do not have. Those antibodies are termed isoagglutinins. Isoagglutinins are antibodies that can react with the blood type antigens on the cells of the organ being transplanted. For instance, blood type O individuals have A and B isoagglutinins, blood type B individuals have A, blood type A individuals have B, and blood type AB individuals have no isoagglutinins.

When an incompatible transplantation takes place, such as transplanting a blood type B organ into a blood type O individual, that organ would likely be rejected immediately. The rejection occurs because the B isoagglutinins in the blood type O recipient react with the B antigens on the vessels of the transplanted organ.
Eighty percent of blood type A and AB persons are subtype A₁ and A₁B, respectively. The other 20% of these blood types are subtype non-A₁. Most often the subtype is A₂ (or A₂B), but occasionally it may be a more rare subtype like A₃, A_{int}, etc. Blood type A, non-A₁ individuals express only about 20% of the normal level of type A antigen on their RBCs and organs. A₁ subtyping is not routinely performed in compatibility testing; however, some patients and donors may be identified as A, non-A₁ or AB, non-A₁B in the course of routine blood bank typing because they have anti-A₁ antibody in their plasma (1-8% of type “A, non-A₁,” and 25% of type “AB, non-A₁B” persons¹).

**Why does it matter?**

An ABO subtype (A₁ vs. A, non-A₁) allows organs to be allocated to additional candidates for both deceased and living donor transplants. A person who is primary blood type A normally could not donate their organ to a candidate who is blood type B. If the person who is blood type A also has a non-A₁ subtype, then they could possibly donate a kidney to a person who is primary blood type B (or O), depending on other factors.

**When should we use and not use subtyping results for allocation?**

Subtyping results can only be used when both samples were obtained before any RBC transfusions, and subtype testing results (both initial and confirmatory) are clear, valid, and match each other. You must not use subtype testing if you question the validity or interrelation of the ABO subtype testing results or if pre-transfusion specimens are not available for both initial and confirmatory subtyping testing. In these situations, the safest approach is to allocate the organs based on the donor’s primary blood type only. It is inconsistent with OPTN Policy to use two out of three results if even one of the results does not indicate the same subtype. Conflicting results include those from transplant hospital or another lab if reported to the OPO prior to or during allocation.

**What can interfere with test results?**

If a donor recently received an RBC transfusion, the A₁ subtyping result may be inaccurate and therefore you should obtain all subtyping samples before RBC transfusions occur. Plasma and platelet transfusions do not affect RBC typing results.

For example, if you gave an organ donor an emergency blood type O RBC transfusion before you collected the subtyping specimen, then the A₁ typing could be inaccurate. Experiments with *in-vitro* mixtures of blood type O and A₁ RBCs suggest that A₁ typing could become falsely negative if more than 75% of the RBCs are type O ². Since it is difficult to estimate precisely how many units of blood type O RBCs need to be given to affect the efficacy of the test (as this depends on the patient’s size, amount and rate of blood loss, timing of the transfusions and intravascular volume status) you must obtain all samples before RBC transfusion.

In the event that the potential donor received a RBC transfusion in the past (as opposed to the current hospitalization), then OPOs and transplant hospitals must determine the time, if any, since transfusion that they consider safe to perform subtype testing. Currently no data identifies how many blood type A RBC transfusions it may take to change the subtyping result from non-A₁ (A₁ negative) to A₁. Transfused RBCs have a half-life of 30 days and the “youngest” RBCs in the blood bag would circulate for up to 120 days.

**Infants and Neonates**

Neonates and infants do not fully express their ABO antigens. Manufacturers of anti-A₁ lectin also have varying warnings in their package inserts such as “results should be interpreted with caution in infants:

² Glenn Ramsey et al., “Abstract Presentations from the AABB Annual Meeting and CTTXPO, Baltimore, MD, October 9-12, 2010,” Transfusion 50 (2010): 166A.
less than one year of age”\textsuperscript{3} and “cord blood and specimens from infants cannot be accurately typed with anti-A1 lectin since the A1 antigen is not fully developed on red blood cells until the age of six months”\textsuperscript{4}. Umbilical cord blood is another consideration for neonates and it is generally recommended that you not use cord blood cells to determine primary ABO or subtype. OPO and transplant programs should consult with their blood banks to consider this issue and adjust practices accordingly.

\textbf{What do the results say?}

The wide range of terminologies used by blood banks and manufacturers to describe subtyping results is confusing. It is particularly confusing when transplant programs or OPOs need to identify the accurate subtyping for transplant compatibility. As mentioned earlier, the actual subtype test looks for whether a blood type A or AB donor’s RBCs react with anti-A\textsubscript{1} lectin. The following tables provide subtype terminology used by the OPTN, along with synonymous terms that you may also see on typing results.

\textbf{Blood Type A Subtype Reporting Terminology:}

<table>
<thead>
<tr>
<th>OPTN</th>
<th>A\textsubscript{1}</th>
<th>A\textsubscript{1} non-A\textsubscript{1}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other terms used</td>
<td>A\textsubscript{1} positive</td>
<td>A\textsubscript{1} negative</td>
</tr>
<tr>
<td></td>
<td>A\textsubscript{1} reactive</td>
<td>Non A\textsubscript{1}</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>A\textsubscript{2}</td>
</tr>
</tbody>
</table>

\textbf{Blood Type AB Subtype Reporting Terminology:}

<table>
<thead>
<tr>
<th>OPTN</th>
<th>A\textsubscript{1} B</th>
<th>AB, non-A\textsubscript{1} B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other terms used</td>
<td>AB, A\textsubscript{1} positive</td>
<td>AB, A\textsubscript{1} negative</td>
</tr>
<tr>
<td></td>
<td>AB, A\textsubscript{1} reactive</td>
<td>AB, A\textsubscript{1} non-reactive</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>A\textsubscript{2}B</td>
</tr>
</tbody>
</table>

When reporting to the OPTN Contractor, A\textsubscript{2} is used as shorthand for any blood type A subtype other than A\textsubscript{1} (i.e. non-A\textsubscript{1}, negative for A\textsubscript{1}). A\textsubscript{2}B is used as shorthand for any blood type AB subtype other than A\textsubscript{1}B (i.e. non-A\textsubscript{1}B, negative for A\textsubscript{1}B).

\textbf{Common issues in subtype reporting:}

- Some of the most common issues found in reviewing and reporting subtype results include:
  - Unclear subtyping results
  - Uncertainty whether the term negative or positive refers to Rh factor or subtype
  - Discordant results (results that do not seem to indicate the same subtype)
  - Not knowing the time of the last transfusion
  - Not knowing if the donor had a transfusion at a prior health care facility or in transit

\textbf{What should I do when I am not sure how to report results?}

A patient’s age, transfusion status, and testing methods of the laboratory can all affect the efficacy of the test. If you have questions about how to interpret subtyping results or whether testing was performed

\textsuperscript{3} Anti-A1 Lectin Package Insert, Core Diagnostics LTD.
\textsuperscript{4} IFY H241Dolichos-A1 Lectin Anti-A1 Ver 1.0 2015, Hemo Bioscience
accurately, your safest approach is to report and allocate the organs based on the donor’s primary blood type and not to consider subtyping. For all blood type A donors, the host OPO must document either that subtyping was completed or the reason it could not be completed.

**More technical information about subtyping**

Determination of a donor’s A1 RBC subtype is performed with anti-A1 lectin, an FDA-approved test reagent. Lectins are non-antibody proteins, which bind with high specificity to a particular carbohydrate structure. Anti-A1 lectin is extracted from the lentil-like seeds of the plant Dolichus biflorus (horse gram). Anti-A1 lectin binds to the A1 carbohydrate and agglutinates A1 or A1B RBCs in a suspension. When type A or AB RBCs are not agglutinated by anti-A1 lectin, the RBCs are negative for A1.

Strictly speaking, there is no (non-DNA) test for the A2 antigen—only a test for whether the A1 antigen is present or not. Therefore, when a blood type A donor does not test positive for A1, the result is called an A, non-A1. Other type A variants exist. One type A variant called A_int (intermediate) is partway between A1 and A2 in strength and can give weak reactions in A1 typing. A_int is found most often in blood type A African-Americans (5-8%). All of the other type A variants, such as A3, A_end, and A_x, are rarely seen (<1:1000 type A persons) and are much weaker in expression overall than type A, non-A1, and therefore presumably would be equivalent to non-A1 for organ-transplant purposes. Laboratories using anti-A1 lectin testing should follow the manufacturer’s directions carefully.

From the perspective of transplant safety, any reaction with anti-A1 lectin, when performed according to the manufacturer’s directions, should be regarded as positive or reactive for A1. This would not be considered safe for potential use as a non-A1 donor by the transplant program, unless proven otherwise. OPO and transplant programs should consult with their blood banks if needed regarding guidance or additional questions.

**Who can help?**

Your local blood bank is a great resource. OPOs and transplant hospitals should establish a relationship with them as they can advise on protocol development and answer questions. Other national groups such as the American Association of Blood Banks (AABB) (http://www.aabb.org/Pages/default.aspx) have additional resources.

**Resources to learn more**

- UNOS Connect, the location for all your transplant education materials, is available at:
  
  [https://unosconnect.unos.org/](https://unosconnect.unos.org/)

  Two courses are available on UNOS Connect that relate to subtyping:

  - ABO Subtyping (SFT 116)
  - ABO Typing and Subtyping (SYS104)


  [https://optn.transplant.hrsa.gov/resources/guidance/](https://optn.transplant.hrsa.gov/resources/guidance/)

- You can also find resources organized by specific organ types:

  - Kidney and pancreas
  - Liver and intestine
  - Heart and lung
  - Vascularized composite allograft

#